Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31443000 | 1.00 | TPMT (0.42) | TPMTGPBAR1HIF1AALOX15TSHR | |
| Nitrous Acid SCHEMBL28567917 | 0.93 | GPBAR1 (0.39) | TPMTGPBAR1HIF1AALOX15TSHR | |
| SCHEMBL12098246 | 0.86 | ALOX15 (0.48) | HIF1AALOX15TSHRLOXL2 | |
| SCHEMBL18050067 | 0.84 | GPBAR1 (0.41) | GPBAR1HIF1ALMNA | |
| SCHEMBL29723389 | 0.84 | GPBAR1 (0.44) | GPBAR1HIF1AHPGDMAPT | |
| SCHEMBL23411999 | 0.84 | GPBAR1 (0.44) | GPBAR1HIF1AHPGDMAPT | |
| SCHEMBL5527447 | 0.81 | TPMT (0.42) | TPMTHIF1AALOX15TSHRLMNA | |
| SCHEMBL29603089 | 0.80 | NOTUM (0.50) | GPBAR1HIF1ALMNAPOLBMAPT | |
| SCHEMBL20186698 | 0.80 | NOTUM (0.50) | GPBAR1HIF1ALMNAPOLBMAPT | |
| 2,6-Dichloroisonicotinic Acid SCHEMBL56204 | 0.80 | TPMT (0.56) | TPMTHIF1AALOX15TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527325-B2 | Pesticidally active diazine-amide compounds | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-20 | — | — | US | disclosed |
| US-12514858-B2 | CD38 inhibitors | Astellas Engineered Small Molecules US, Incorporated (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025131957-A1 | DIAZINONE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-3947358-B1 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| US-12281095-B2 | Pesticidally active diazine-amide compounds | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-22 | — | — | US | disclosed |
| CN-115697985-B | CD38 inhibitors | 米托布里奇公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-117903077-B | Dihydrooxadiazinone compound and application thereof | 上海超阳药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024156938-A1 | CBL-B INHIBITORS | ORION CORPORATION (FI) | 2024-08-02 | — | — | WO | disclosed |
| CN-117903077-A | Dihydrooxadiazinon compound and application thereof | 上海超阳药业有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012117000-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| WO-2012068450-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
| US-7745477-B2 | Heteroaryl and benzyl amide compounds | HOFFMAN-LA ROCHE INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1984322-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527325-B2 | Pesticidally active diazine-amide compounds | DDT, CHRM1, C3AR1 | TPMT 4461/4885GPBAR1 2368/4885HIF1A 3842/4885 |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | TPMT 1496/4885GPBAR1 1/4885HIF1A 700/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | TPMT 1704/4885GPBAR1 399/4885HIF1A 2390/4885 |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | TPMT 230/4885GPBAR1 4313/4885HIF1A 3208/4885 |
| US-12281095-B2 | Pesticidally active diazine-amide compounds | DDT, ACHE, NIT2 | TPMT 2555/4885GPBAR1 2382/4885HIF1A 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.